Resolution of established cardiac hypertrophy and fibrosis and prevention of systolic dysfunction in a transgenic rabbit model of human cardiomyopathy through thiol-sensitive mechanisms

Circulation

Volumn 119, Issue 10, 2009, Pages 1398-1407

  Lombardi, Raffaella ^d   Rodriguez, Gabriela ^d   Chen, Suet Nee ^a   Ripplinger, Crystal M ^c   Li, Wenwen ^c   Chen, Junjie ^c   Willerson, James T ^d   Betocchi, Sandro ^b   Wickline, Samuel A ^c   Efimov, Igor R ^c   Marian, Ali J ^d  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c WASHINGTON UNIVERSITY IN ST LOUIS   (United States)

^d Center for Cardiovascular Genetics   (United States)

Author keywords

Antioxidants; Cardiomyopathy; Fibrosis; Genetics; Hypertrophy

Indexed keywords

ACETYLCYSTEINE; ALPHA ACTIN; CYCLIC GMP DEPENDENT PROTEIN KINASE; G ACTIN; GLUTATHIONE; MITOGEN ACTIVATED PROTEIN KINASE P38; MYOSIN HEAVY CHAIN BETA; PLACEBO; THIOL GROUP; TRANSCRIPTION FACTOR NFAT; ACTIN; ANTIOXIDANT; MYOSIN HEAVY CHAIN; THIOL DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOMYOPATHY; DEPHOSPHORYLATION; FEMALE; FIBROSING ALVEOLITIS; HEART DISEASE; HEART MUSCLE FIBROSIS; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE HYPERTROPHY; MALE; NONHUMAN; OXIDATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; RABBIT; SYSTOLIC DYSFUNCTION; TRANSGENIC ANIMAL; ANIMAL; CELL SIZE; DISEASE MODEL; DRUG EFFECT; FIBROSIS; GENETICS; HEART MUSCLE CELL; HEART VENTRICLE FIBRILLATION; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; SYSTOLIC HEART FAILURE;

ACETYLCYSTEINE; ACTINS; ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTIOXIDANTS; CARDIOMYOPATHY, HYPERTROPHIC; CELL SIZE; DISEASE MODELS, ANIMAL; FEMALE; FIBROSIS; GLUTATHIONE; HEART FAILURE, SYSTOLIC; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MYOCYTES, CARDIAC; MYOSIN HEAVY CHAINS; NFATC TRANSCRIPTION FACTORS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; RABBITS; SULFHYDRYL COMPOUNDS; VENTRICULAR FIBRILLATION;

EID: 64549096033     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.108.790501     Document Type: Article

References (38)

1. Haider AW, Larson MG, Benjamin EJ, Levy D. Increased left ventricular mass and hypertrophy are associated with increased risκ for sudden death. J Am Coll Cardiol. 1998;32:1454-1459.
2. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322:1561-1566.
3. Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ. Magnitude of left ventricular hypertrophy and risκ of sudden death in hypertrophic cardiomyopathy. N Engl J Med. 2000;342:1778-1785.
4. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure, part II: causal mechanisms and treatment. Circulation. 2002;105:1503-1508.
5. Hill JA, Olson EN. Cardiac plasticity. N Engl J Med. 2008;358:1370 -1380.
6. Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA. 2002;287:1308-1320.
7. Marian AJ. Genetic determinants of cardiac hypertrophy. Curr Opin Cardiol. 2008;23:199-205.
8. Marian AJ, Wu Y, Lim DS, McCluggage M, Youκer K, Yu QT, Brugada R, DeMayo F, Quinones M, Roberts R. A transgenic rabbit model for human hypertrophic cardiomyopathy. J Clin Invest. 1999;104:1683-1692.
9. Nagueh SF, Chen S, Patel R, Tsybouleva N, Lutucuta S, Kopelen HA, Zoghbi WA, Quinones MA, Roberts R, Marian AJ. Evolution of expression of cardiac phenotypes over a 4-year period in the beta-myosin heavy chain-Q403 transgenic rabbit model of human hypertrophic car-diomyopathy. J Mol Cell Cardiol. 2004;36:663-673.
10. Nagueh SF, Kopelen HA, Lim DS, Zoghbi WA, Quinones MA, Roberts R, Marian AJ. Tissue Doppler imaging consistently detects myocardial contraction and relaxation abnormalities, irrespective of cardiac hypertrophy, in a transgenic rabbit model of human hypertrophic cardiomyop-athy. Circulation. 2000;102:1346-1350.
11. Patel R, Nagueh SF, Tsybouleva N, Abdellatif M, Lutucuta S, Kopelen HA, Quinones MA, Zoghbi WA, Entman ML, Roberts R, Marian AJ. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hyper- trophic cardiomyopathy. Circulation. 2001;104:317-324.
12. Senthil V, Chen SN, Tsybouleva N, Halder T, Nagueh SF, Willerson JT, Roberts R, Marian AJ. Prevention of cardiac hypertrophy by atorvastatin in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circ Res. 2005;97:285-292.
13. Marian AJ, Senthil V, Chen SN, Lombardi R. Antifibrotic effects of antioxidant N-acetylcysteine in a mouse model of human hypertrophic cardiomyopathy mutation. J Am Coll Cardiol. 2006;47:827-834.
14. Tirouvanziam R, Conrad CK, Bottiglieri T, Herzenberg LA, Moss RB, Herzenberg LA. High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis. Proc Ntl Acad Sci. 2006;103:4628-4633.
15. Taκimoto E, Kass DA. Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension. 2007;49:241-248.
16. Williams IA, Allen DG. The role of reactive oxygen species in the hearts of dystrophin-deficient mdx mice. Am J Physiol. 2007;293:H1969-H1977.
17. Ripplinger CM, Li W, Hadley J, Chen J, Rothenberg F, Lombardi R, Wicκline SA, Marian AJ, Efimov IR. Enhanced transmural fiber rotation and connexin 43 heterogeneity are associated with an increased upper limit of vulnerability in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circ Res. 2007;101:1049-1057.
18. Chen J, Song SK, Liu W, McLean M, Allen JS, Tan J, Wicκline SA, Yu X. Remodeling of cardiac fiber structure after infarction in rats quantified with diffusion tensor MRI. Am J Physiol. 2003;285:H946-H954.
19. Hitchcocκ SE. Actin deoxyroboncuclease I interaction: depolymerization and nucleotide exchange. J Biol Chem. 1980;255:5668-5673.
20. Cox B, Emili A. Tissue subcellular fractionation and protein extraction for use in mass-spectrometry-based proteomics. Nat Protocols. 2006;1:1872-1878.
21. Cross JV, Templeton DJ. Regulation of signal transduction through protein cysteine oxidation. Antioxid Redox Signal. 2006;8:1819-1827.
22. Molκentin JD. Calcineurin-NFAT signaling regulates the cardiac hyper- trophic response in coordination with the MAPKs. Cardiovasc Res. 2004; 63:467-475.
23. Burgoyne JR, Madhani M, Cuello F, Charles RL, Brennan JP, Schroder E, Browning DD, Eaton P. Cysteine redox sensor in PKGIa enables oxidant-induced activation. Science. 2007;317:1393-1397.
24. Fiaschi T, Cozzi G, Raugei G, Formigli L, Ramponi G, Chiarugi P. Redox regulation of beta-actin during integrin-mediated cell adhesion. J Biol Chem. 2006;281:22983-22991.
25. Dalle-Donne I, Giustarini D, Colombo R, Milzani A, Rossi R. S-Glutathionylation in human platelets by a thiol-disulfide exchange- independent mechanism. Free Radic Biol Med. 2005;38:1501-1510.
26. Vartiainen MK, Guettler S, Larijani B, Treisman R. Nuclear actin regulates dynamic subcellular localization and activity of the SRF cofactor MAL. Science. 2007;316:1749-1752.
27. Demasi M, Silva GM, Netto LE. 20 S proteasome from Saccharomyces cerevisiae is responsive to redox modifications and is S-glutathionylated. J Biol Chem. 2003;278:679-685.
28. Zafarullah M, Li WQ, Sylvester J, Ahmad M. Molecular mechanisms of N-acetylcysteine actions. Cell Mol Life Sci. 2003;60:6-20.
29. Demedts M, Behr J, Buhl R, Costabel U, Deκhuijzen R, Jansen HM, MacNee W, Thomeer M, Wallaert B, Laurent F, Nicholson AG, Verbeκen EK, Verschaκelen J, Flower CDR, Capron F, Petruzzelli S, De Vuyst P, van den Bosch JMM, Rodriguez-Becerra E, Corvasce G, Lanκhorst I, Sardina M, Montanari M, IFIGENIA Study Group. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2005;353:2229-2242.
30. Kopp J, Seyhan H, Muller B, Lanczaκ J, Pausch E, Gressner AM, Dooley S, Horch RE. N-Acetyl-L-cysteine abrogates fibrogenic properties of fibroblasts isolated from Dupuytren's disease by blunting TGF-beta signalling. J Cell Mol Med. 2006;10:157-165.
31. Liu RM, Liu Y, Forman HJ, Olman M, Tarpey MM. Glutathione regulates transforming growth factor-{beta}-stimulated collagen production in fibroblasts. Am J Physiol. 2004;286:L121-L128.
32. Hoshiκawa Y, Ono S, Suzuκi S, Tanita T, Chida M, Song C, Noda M, Tabata T, Voelκel NF, Fujimura S. Generation of oxidative stress contributes to the development of pulmonary hypertension induced by hyp-oxia. J ApplPhysiol. 2001;90:1299-1306.
33. Liu DD, Kao SJ, Chen HI. N-Acetylcysteine attenuates acute lung injury induced by fat embolism. Crit Care Med. 2008;36:565-571.
34. Miralles F, Posern G, Zaromytidou AI, Treisman R. Actin dynamics control SRF activity by regulation of its coactivator MAL. Cell. 2003; 113:329 -342.
35. Atκuri KR, Mantovani JJ, Herzenberg LA, Herzenberg LA. N-Acetyl- cysteine: a safe antidote for cysteine/glutathione deficiency. Curr Opin Pharmacol. 2007;7:355-359.
36. De Rosa SC, Zaretsκy MD, Dubs JG, Roederer M, Anderson M, GreenA, Mitra D, Watanabe N, Naκamura H, Tjioe I, Deresinsκi SC, Moore WA, Ela SW, Parκs D, Herzenberg LA. N-Acetylcysteine replenishes gluta-thione in HIV infection. Eur J Clin Invest. 2000;30:915-929.
37. Palmer LA, Doctor A, Chhabra P, Sheram ML, Laubach VE, Karlinsey MZ, Forbes MS, Macdonald T, Gaston B. S-Nitrosothiols signal hypox- ia-mimetic vascular pathology. J Clin Invest. 2007;117:2592-2601.
38. Lachmanova V, Hnilicκova O, Povysilova V, Hampl V, Herget J. N-Acetylcysteine inhibits hypoxic pulmonary hypertension most effectively in the initial phase of chronic hypoxia. Life Sci. 2005;77:175-182.